European Archives - Page 1249 of 1555 - European Medical Journal

Targeting the Relaxin Pathway for Liver Disease Treatment

Hepatic fibrosis is a progressive disease with few treatment options outside of transplantation. Relaxin is a member of the insulin/relaxin superfamily…

Monocyte-Derived Hepatocyte-Like Cells in Combination with Proteomics Identify a Potential Biomarker for Drug-Induced Liver Injury by Diclofenac

Drug-induced liver injury (DILI) is the leading cause of acute liver failure leading to death or requiring transplantation in the European Union (EU) and…

Thermal Ablation of Liver Tumours: How the Scenario Has Changed in the Last Decade

Surgical resection has long been considered the gold standard for the local treatment of primary and secondary liver tumours. Until recent years…

Percutaneous Laser Thermal Ablation in a Patient with 22 Liver Metastases from Pancreatic Neuroendocrine Tumours: A Case Report

The relatively indolent nature of well-differentiated neuroendocrine tumours (NET) and their proclivity to be hormonally active warrants aggressive…

Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?

Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease that is characterised by steatosis, chronic inflammation, and…

Positive Impact of Exergaming on Heart Failure Patients

‘Exergaming’ can improve quality of life for heart failure patients, according to a new study presented in an ESC press release.

Bacteriophages Reveal the Hidden Potential of Bacteria

Bacteriophages can help bacteria develop new functions by revealing their hidden potential, according to a study from Uppsala University, Uppsala…

This May 2018, EMJ Supports…

This May, EMJ has proudly showcased its support for World Lupus Day, Sun Awareness Week, and Make May Purple.

Preview of the 23rd Congress of the European Hematology Association (EHA)

The world-renowned Stockholmsmässan congress centre in Stockholm, Sweden, will host this year’s EHA Congress, which promises to be a particularly…

An Experimental Approach for Glioblastoma Treatment

Glioblastoma patients have a median survival of 10–12 months due to this aggressive brain cancer, which affects astrocytes, develops rapidly, and recurs…